臺灣人文及社會科學引文索引資料庫系統

:::

詳目顯示

回上一頁
第 1 筆 / 總合 1 筆   第一頁 上一頁 下一頁 最後一頁
/1頁
題名：從TRIPS協定談專利法第99條之解釋
書刊名：興大法學
作者：陳秉訓 引用關係
作者(外文)：Chen, Ping-hsun
出版日期：2015
卷期：17
頁次：頁141-187
主題關鍵詞：製程方法專利；舉證責任；TRIPS協定；專利法第99條；Process patent；Burden of proof；TRIPS Agreement；Article 99 of the Patent Act
原始連結：連回原系統網址new window
相關次數：
  • 被引用次數被引用次數:期刊(0) 博士論文(0) 專書(0) 專書論文(0)
  • 排除自我引用排除自我引用:0
  • 共同引用共同引用:55
  • 點閱點閱:21
專利法第99條第1項規定：「製造方法專利所製成之物在該製造方法申請專利前，為國內外未見者，他人製造相同之物，推定為以該專利方法所製造」。此為製造方法專利侵害之舉證責任反轉之規定，但該條之「在該製造方法申請專利前」在系爭專利有主張優先權時是否包括「優先權日前」則屬不明確。智慧財產法院民事判決99年度民專訴字第159號解決此問題，而讓第99條第1項判斷的時間點，對於有主張優先權之專利，從文義上的「申請日」可提早至「優先權日」。不過，本案判決的法律解釋卻不是直接的論述，因而本文意在補充法律論證上之不足。透過TRIPS協定第34條的解釋，本文認為該判決之解釋方向是合理的，且也能完善國際優先權制度。進一步，本文認為「製造方法專利所製成之物」應適度排除製造方法專利權人所生產之物，或至少應排除其於新穎性優惠期期間內所公開之物。此觀點同樣基於對TRIPS協定第34條的解釋，以及考慮專利法第99條的立法理由和專利法內在的和諧。
Article 99, Paragraph 1 of the Patent Act provides, “If the product made by the process patent has never been seen in this or foreign country before the patent application for such process was filed, a product made by others is presumed to be made by such patented pro-cess.” This provision relates to the reversal of burden of proof for a process patent, but does not clarify whether “before the patent appli-cation for the process was filed” covers the date a patentee claims for a right of priority. Taiwan Intellectual Property Court Civil Judgment (99) Min Zhuan Su Zi No. 159 (2010) may resolve this issue and im-plies that the literal meaning of the timing term in Article 99, Paragraph 1 for determining the novelty of “the product made by the process pa-tent” may be changed from the “actual filing date” to “priority date” if the patent enjoys the right of priority. But, the court did not interpret the statute directly. So, this article is intended to provide legal argu-ments to support the court. According to the interpretation of Article 34 of the TRIPS Agreement, this article supports the reasonableness of the court’s implication that can improve the law of a right of priority. Moreover, this article proves that the scope of “the product made by the process patent” should exclude the product made by the process patent owner, or at least the product disclosed publicly by the patentee during the grace period. This view is supported by the interpretation of Article 34 of the TRIPS Agreement, legislative history of Article 99 of the Patent Act, and the consideration of the internal harmonization of the Patent Act.
期刊論文
1.Kongolo, Tshimanga(2002)。Morocco’s Patent System and its International Connection。IDEA，42，181。  new window
2.李耀泰、陳福民、侯廣瓊、鄭文雄、郭宗正(20080400)。Docetaxel治療卵巢癌之檢視。中華民國婦癌醫學雜誌，2008(1)，7-13。  延伸查詢new window
3.林更盛(20120300)。論法律解釋的目標。高大法學論叢，7(2)，1-40。new window  延伸查詢new window
4.洪長春(20070700)。天然抗癌物的新尖兵--紫杉醇。科技發展政策報導，4，80-83。  延伸查詢new window
5.張睿哲、鍾文正、文治中、陳瀅安、林坤隆、林明立(20131200)。優惠期制度之國際調和與發展。智慧財產權，180，5-32。new window  延伸查詢new window
6.傅慈雅、陳倉戌(20080700)。疑似Docetaxel引起的心律不整--案例報告。澄清醫護管理雜誌，4(3)，33-39。  延伸查詢new window
7.Bertram, Elana A.(2011)。How to Keep Your Invention Patentable While It is Stored in the Cloud: A Guide for Small Inventors。ED. CIRCUIT B.J.，21，389。  new window
8.Case, Jennifer L.(2013)。How the America Invents Act Hurts American Inventors and Weakens Incentives to Innovate。UMKC L. Rev.，82，29。  new window
9.Correa, Carlos M.(1994)。The GATT Agreement on Trade-Related Aspects of Intellectual Property Rights: New Standards for Patent Protection。E. I. P. R.，16(8)，327。  new window
10.Fernandes, Siddharth(2008)。A Realistic Analysis of §271(g) and the ITC: Academic Hypotheses Aside, §271(g) does not Violate the Paris Convention or TRIPS Because its Affirmative Defenses do not Apply to §337 Actions Before the ITC。FED. CIRCUIT B. J.，17，473。  new window
11.Foster, George K.(1998)。Comment, Opposing Forces in a Revolution in International Patent Protection: The U.S. and India in the Uruguay Round and Its Aftermath。UCLA Journal of International Law and Foreign Affair，3。  new window
12.Frisvold, George、Kelly, Day-Rubenstein(2008)。Bioprospecting and Biodiversity Conservation: What Happens When Discoveries Are Made?。ARIZ. L. Rev.，50，545。  new window
13.Halasz, Ty, Comments(2012)。The Game of the Name: Shortcomings in the Dual-Agency Review of Drug Trademarks and a Remedial Cure。ADMIN. L. REV.，64，235。  new window
14.Hason, Averie K.、Shimotake, Jean E.(2006)。Recent Developments in Patent Rights for Pharmaceuticals in China and India。PACE INT’L L. REV.，18，303。  new window
15.Heo, Jae Ho(2009)。Development of New Efficient Synthetic Methods for Docetaxel。BULL. KOREAN CHEN. SOC.，30(1)，25。  new window
16.Hicks, Laurinda L.(1997)。Convergence of National Intellectual Property Norms in International Trading Agreements。AM. U. J. INT’L L. & POL’Y，12，769。  new window
17.Lesser, William(2011)。Measuring Intellectual Property ‘Strength’ and Effects: An Assessment of Patent Scoring Systems and Causality。J. BUS. ENTREPRENEURSHIP & L.，4，345。  new window
18.Li, Anne Elise Herold(2006)。Is the Federal Circuit Affecting U.S. Treaties? The ITC, § 271(g), GATT/TRIPS & the Kinik Decision。FORDHAM INTELL. PROP. MEDIA & ENT. L. J.，16，601。  new window
19.Liu, Benjamin Piwei(2012)。Chinese Patents as Copyrights。CAMPBELL L. REV.，34，685。  new window
20.Matthews, Duncan、Wilson, Caroline(1998)。Pharmaceutical Regulation in the Single European Market。Med. & L.，17，401。  new window
21.Mercurio, Bryan、Tyagi, Mitali(2010)。Treaty Interpretation in WTO Dispute Settlement: The Outstanding Question o f the Legality of Local Working Requirements。MINN. J. INT’L L.，19，275。  new window
22.Metzler, Renee E.(2009)。Not All Grace Periods are Created Equal: Building a Grace Period from the Ground Up。MARQ. INTELL. PROP. L. REV.，13，371。  new window
23.Mueller, Janice M.(2007)。Biotechnology Patenting in India: Will Bio-Generics Lead a “Sunrise Industry” to Bio-Innovation?。UMKC L. Rev.，76，437。  new window
24.Mueller, Janice M.(2007)。The Tiger Awakens: The Tumultuous Transformation of India’s Patent System and the Rise of Indian Pnarmaceutical Innovation。U. PITT. L. Rev.，68，491。  new window
25.Sell, Susan K.(2002)。Industry Strategies for Intellectual Property and Trade: The Quest for TRIPS, and Post-TRIPS Strategies。CARDOZO J. INT’L & COMP. L.，10，79。  new window
26.Shanker, Daya(2004)。Argentina-US Mutually Agreed Solution, Economic Crisis in Argentina and Failure of the WTO Dispute Settlement System。IDEA，44，565。  new window
27.SKinner, Jonathan(2011)。Overcoming Babel’s Curse: Adapting the Doctrine of Foreign Equivalents。J. PAT. & TRADEMARK OFF. SOC’Y，93，57。  new window
28.Sorell, Louis S.(2002)。A Comparative Analysis of Selected Aspects of Patent Law in China and the United States。PAC. RIM L. & POL’Y J.，11，319。  new window
29.Straus, Joseph(2012)。A Marriage of Convenience: World Economy and Intellectual Property from 1990 to 2012。AIPLA Q. J.，40，633。  new window
30.Sun, Andy Y.(1998)。From Pirate King to Jungle King: Transformation of Taiwan’s Intellectual Property Protection。FORDHAM INTELL. PROP. MEDIA &ENT. L. J.，9，67。  new window
31.Trias de Bes、Miguel, Vidal-Quadras(2002)。Process Patents on New Products and Reversal of the Burden of Proof: Factors Contributing to the Interpretation of Its Scope。E. I. P. R.，24(5)，237。  new window
32.Unnl, Venugopal K.(2012)。Indian Patent Law and TRIPS: Redrawing the Flexibility Framework in the Context of Public Policy and Health。PAC. MCGEORGE GLOBAL BUS. & DEV. L. J.，25，323。  new window
33.World Health Organization(1993)。Proposed INN List 70 International Nonproprietary Names for Pharmaceutical Substances。WHO DRUG Information，7(4)，203。  new window
34.WHO(1990)。Proposed International Nonproprietary Names (Proposed INNs): List 63。WHO Drug Information，4(2)，1。  new window
35.WHO(1992)。Amendments to Previous Lists。WHO DRUG INFORMATION，6(4)，15。  new window
36.Zanzig, Laura(2013)。The Perfect Pairing: Protecting U.S. Geographical Indications with a Sino-American Wine Registry。WASH. L. REV.，88，723。  new window
37.Reed, Brad(2013)。Google’s Latest ‘Moonshot’ May Be a Flying Car。  new window
38.WHO(2013)。Lists of Recommended and Proposed INNs。  new window
39.Chen, Quincy(2011)。Destroying a Pharmaceutical Patent for Saving Lives? A Case Study of Sano-Synthelabo v. Apotex, Inc.。ALB. L.J. SCI. & TECH.，21，125。  new window
40.李素華(20121100)。專利法第八七條方法專利權侵害之推定--從智慧財產法院九十九年度民專訴字第一五九號民事判決談起。月旦法學，210，162-186。new window  延伸查詢new window
圖書
1.趙晉枚、蔡坤財、周慧芳、謝銘洋、張凱娜(1998)。智慧財產權入門。元照出版有限公司。  延伸查詢new window
2.林洲富(2009)。專利法--案例式。臺北：五南。  延伸查詢new window
3.經濟部智慧財産局(2011)。專利法。經濟部智慧財産局。  延伸查詢new window
4.鄭中人(2009)。專利法規釋義。臺北：考用出版股份有限公司。  延伸查詢new window
5.黃文儀(20000400)。專利法逐條解說。黃文儀。  延伸查詢new window
6.陳文吟(1995)。我國專利制度之研究。五南圖書出版股份有限公司。new window  延伸查詢new window
其他
1.衛生福利部食品藥物管理署(2013)。西藥、醫療器材、含藥化粧品許可證查詢，http://www.fda.gov.tw/MLMS/(S(ueq34w55xpsufm2te3zi3ce5))/H0001.aspx， 2013/12/14。  延伸查詢new window
2.(1989)。Agreement relating to Community Patents art. 35，http://eur-lex.europa.eu/LexUriServ/LexUrIServ.do?url=CELEX:41989A0695(01):EN:HTML， 2015/05/14。  new window
3.AMA(2013)。How to Apply for a Name-Obtain a CAS Registry Name and Number，http://www.ama-assn.org/ama/pub/physician-resources/medicalscience/united-states-adopted-names-council/how-to~applv-for-usan.page?， 2013/12/03。  new window
4.(2013)。American Chemical Society，https://www.cas.org/content/chemicalsubstances/faqs， 2013/11/30。  new window
5.American Medical Association(2013)。How to Apply for a Name-When to Apply，http://www.ama-assn.org/ama/pub/physicianresources/medical-science/united-states-adopted-names-council/how-toapply-for-usan.page?， 2013/12/02。  new window
6.He, John(2013)。Drug in Focus: Docetaxel，http://www.genericsweb.com/index.php?object_id=921， 2013/12/14。  new window
7.Milford, Phil(2009)。Sanofi-Aventis Faces Hospira, Apotex in Patent Trial (Update1)，http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aHzAeMtX92EY， 2015/05/14。  new window
8.Prank, Linda Christina(1997)。Modulation of Docetaxel Treatment，http://repub.eEr.nl/pub/20361/971127_PRONK,%20LInda%20CMstina.pdf， 2015/05/14。  new window
9.WHO(2013)。Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances，http://apps.who.int/medicinedocs/en/d/Jwhozip20b/l.html， 2013/11/30。  new window
10.World Health Organization(1997)。Guidelines on the Use of International Nonproprietary Names (INNS) for Pharmaceutical Substances，http://apps.who.int/medicinedocs/pddi1806e/h1806e.pdf， 2015/05/14。  new window
 
 
 
 
第一頁 上一頁 下一頁 最後一頁 top
:::
無相關著作
 
QR Code
QRCODE

臺灣人文及社會科學引文索引資料庫

目前上線人數：1185（臺灣：1160，外國：25） ／ 本年度總使用人次：1563831 ／ 訪客人次（自102年09月）：67367218
國家圖書館著作權聲明 Copyright © 2013 All rights reserved.
本館地址: 100201臺北市中山南路20號． 本館地圖及交通資訊．
總機：(02)23619132．最佳瀏覽解析度為1024x768以上